June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
July 2023 in “Clinical dermatology review” Intralesional triamcinolone acetonide is better than PRP for treating scalp alopecia areata, leading to faster and more complete hair regrowth.
2 citations
,
June 2024 in “Journal of the American Academy of Dermatology” Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
The treatment was not recommended due to limited effectiveness and significant side effects.
December 2024 in “Medical alphabet” The combination of "Time to Grow" and "Thick and Strong Hair" effectively reduces hair loss and improves hair quality.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
1 citations
,
January 2023 in “Journal of Clinical Medicine” A new hair restoration technology was found to effectively increase hair thickness, density, and growth, while reducing hair loss and improving scalp health, with no side effects.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
February 2023 in “Materials today bio” The treatment effectively promotes hair regrowth in androgenetic alopecia without causing skin irritation.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
July 2023 in “Journal of the American Academy of Dermatology” Clinical trials for alopecia areata need better inclusion and retention of patients of color.
July 2024 in “Chinese Medical Journal” Peripheral blood alive cell treatment is effective and safe for treating hair loss.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
April 2024 in “Current research in nutrition and food science” Taking an amino acid supplement improved skin, hair, and nail health in women.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
June 2021 in “Research Square (Research Square)” Using fat-derived cells to treat hair loss increased hair density and thickness without side effects.
May 2026 in “Institutional Repository of the University of Granada (University of Granada)” New treatments for alopecia areata show promise, but their real-world effectiveness and impact on life and sexual health need more study.
November 2024 in “Journal of Clinical Medicine” The treatment improved hair thickness, shine, and reduced hair loss effectively.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
11 citations
,
April 2015 in “International Journal of Cosmetic Science” Adenosine helps grow thicker hair in Japanese men with hair loss.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
12 citations
,
July 2016 in “Journal of dermatology” Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.